TROUBLE VIEWING? Click Here to view the Promo card on the web
SIGN-UP NOW! Click to become a Member for Free!
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

December 3rd 2019: C. diff. Treatment Option; Oral Vancomycin Solution

Join Us with guest: Karl Kappeler, MS, RPh, FASHP Director, Medical Affairs of Azurity Pharmaceuticals. and will be discussing C. difficile infections, C. diff. treatment options and the Azurity Pharmaceuticals organization with its FDA approved product. Listen in as we learn more about the Company’s history, their unique product offerings that help pharmacists compound drugs, and product information for FIRVANQ, their FDA approved vancomycin oral solution.

Download PDF DOWNLOAD PDF

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live! Call-In
Toll Free:  1-866-472-5792
Intl:  001-480-553-5759

Featured Guest

Guest Image

Karl Kappeler

Mr. Kappeler, Director, Medical Affairs, joined Azurity Pharmaceuticals through the acquisition of Silvergate Pharmaceuticals by CutisPharma in May 2019, forming the new company Azurity. Prior to the acquisition, Mr. Kappeler served as Director, Clinical Information at Silvergate Pharmaceuticals. Prior to joining Silvergate,
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
Facebook Twitter Linkedin Social Media
presspass-banner